phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

ASH 2025: Results Show Long-Lasting Benefits of CAR T Cell Therapy for Hard-to-Treat Lymphoma

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor (CAR) T cell therapy, even after prior treatments have failed, according to researchers at The University of Texas MD Anderson Cancer Center.

December 8, 2025


December 10 2025

December 9 2025

December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025

November 27 2025

Angell Street Psychiatry
Copyright 2025 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy